<DOC>
	<DOC>NCT00241605</DOC>
	<brief_summary>This 48-week study will compare AVANDAMET vs. Metformin monotherapy for blood glucose control in patients with Type 2 Diabetes Mellitus.</brief_summary>
	<brief_title>AVANDAMET Versus Metformin For Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Patients between 18 and 75 years of age with Type 2 Diabetes Mellitus and are currently on metformin monotherapy for glycemic control (100mg daily for at least 3 months prior to screening). Patients must have stopped previous treatment with thiazolidinediones or other antidiabetic agents at least 3 months prior to screening. Women must be postmenopausal, surgically sterile or using acceptable contraceptive measures. Prior history of hepatocellular reaction to or severe edema associated with the use of thiazolidinediones. Have a known hypersensitivity to thiazolidinediones or biguanides. Currently using insulin or any oral antidiabetic agent other than metformin. History of metabolic acidosis. History of substance abuse. Have active cancer other than localized squamous or basal cell carcinoma. Chronic disease requiring treatment with corticosteroids. Other criteria will be evaluated at the screening visit.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Metformin</keyword>
	<keyword>AVANDAMET</keyword>
	<keyword>Type 2 diabetes</keyword>
</DOC>